Overview

SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain

Status:
Active, not recruiting

Trial end date:
2022-12-06

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the long-term efficacy and safety of relugolix 40 milligram (mg) once daily co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) for up to 104 weeks on endometriosis-associated pain in participants who previously completed a 24-week treatment period in one of the parent studies (MVT-601-3101 or MVT-601-3102).

Phase:

Phase 3

Details

Lead Sponsor:

Myovant Sciences GmbH

Treatments:

Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Norethindrone
Norethindrone Acetate
Polyestradiol phosphate
Relugolix